Predict your next investment

HEALTHCARE | Biotechnology
silverbacktx.com

See what CB Insights has to offer

Founded Year

2016

Stage

IPO | IPO

Total Raised

$211M

Date of IPO

12/4/2020

Market Cap

0.17B

Stock Price

4.91

About Silverback Therapeutics

Silverback Therapeutics is a biotechnology company that develops a pipeline of systemically delivered, locally active therapies that can be administered to patients. The active therapies only act at the sites of disease, sparing healthy tissues from unwanted side effects.

Silverback Therapeutics Headquarter Location

500 Fairview Ave N Suite 600

Seattle, Washington, 98109,

United States

206-456-2900

Latest Silverback Therapeutics News

Silverback News (SBTX); Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel

Jan 10, 2022

San Diego, California, UNITED STATES SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX) against certain of its officers and directors. Earlier this year, a class action complaint was filed against Silverback. According to the lawsuit, the IPO documents featured and defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Silverback’s lead product candidate SBT6050 (a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers) was less effective than the Company had represented to investors; (2) accordingly, the Company had overstated SBT6050’s commercial and/or clinical prospects; and (3) as a result, the IPO documents and defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein. When the true details entered the market, the lawsuit claims that investors suffered damages. If you are a current, long-term shareholder of Silverback holding shares before January 2021, you may have standing to hold Silverback (and its shareholders) harmless from the alleged harm caused by the Company's officers and directors by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing. There is no cost or obligation to you.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Silverback Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Silverback Therapeutics in 1 CB Insights research brief, most recently on Mar 24, 2020.

Expert Collections containing Silverback Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Silverback Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Silverback Therapeutics Patents

Silverback Therapeutics has filed 16 patents.

The 3 most popular patent topics include:

  • Immunology
  • Immune system
  • Radiation therapy
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/19/2021

11/23/2021

Monoclonal antibodies, Immune system, Immunology, Clusters of differentiation, Experimental cancer drugs

Grant

Application Date

2/19/2021

Grant Date

11/23/2021

Title

Related Topics

Monoclonal antibodies, Immune system, Immunology, Clusters of differentiation, Experimental cancer drugs

Status

Grant

Silverback Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Silverback Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.